Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN
Recruiting
Observational Study
ABO Hemolytic Disease of Newborn
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- Up to 7 Days
- Sex
- Any
- Study type
- Observational
- Participants needed
- 112 (estimated)
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A prospective observational cohort study was designed.
1. Comparing of the clinical indicators between the hemolytic group and the non-hemolytic group,such as End-tidal carbon monoxide corrected for ambient CO(ETCOc),direct antiglobulin test(DAT), the highest total serum bilirubin level and hemoglobin. To explore the role of ETCOc in the diagnosis of neonatal ABO hemolytic disease.
2. Comparing o…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* gestational age between 35+0 and 41+6 weeks
* birth weight ≥ 2500 grams
* respiratory rate \< 60 breaths per minute
* the neonates admitted to the neonatology department for phototherapy because of hyperbilirubinemia that conforms to the guideline of the experts consensus on t…
Contacts